معرفی
Giorgio Trinchieri, M.D. serves as Chief of the Laboratory of Integrative Cancer Immunology and NIH Distinguished Investigator at the National Cancer Institute's Center for Cancer Research. His leadership encompasses intramural laboratories central to NCI's inflammation and cancer initiative, bridging immunology expertise with carcinogenesis research.
Education:
- Medical Degree (M.D.) from University of Torino, Italy
Dr. Trinchieri's research revolutionized understanding of inflammation-immunity-cancer interfaces, particularly through his 1989 discovery of interleukin-12. His current work focuses on microbiome-cancer interactions, dendritic cell biology, and cytokine networks in carcinogenesis. Key investigations examine how commensal microbiota and inflammatory mediators influence tumor progression and immunotherapy response, with emphasis on plasmacytoid dendritic cells and Toll-like receptor signaling pathways.
Recent publications reveal groundbreaking connections between gut microbiome composition and immunotherapy efficacy, demonstrating how fecal transplants and dietary interventions overcome treatment resistance in melanoma. His work establishes microbiome modulation as a critical therapeutic avenue in oncology.
Scientific Honors:
- NIH Distinguished Investigator (2016)
As laboratory chief, Dr. Trinchieri directs a multidisciplinary team of staff scientists, fellows, and technicians investigating inflammation-cancer crosstalk. His intramural research program at NCI integrates basic immunology with translational applications, supported by NIH funding mechanisms. Current initiatives focus on reversing immunosuppressive tumor microenvironments through microbiome-targeted strategies.
The Laboratory of Integrative Cancer Immunology maintains active collaborations across NCI's Bethesda and Frederick campuses, with particular emphasis on experimental models of colon and skin carcinogenesis. Ongoing work explores STAT3 signaling, macrophage polarization, and microbial metabolite effects on tumor immunity.
